Brain and Nervous System
7
2
2
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
Auricular Stimulation for Functional Dyspepsia With Insomnia: Efficacy and Mechanisms
Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma
Using a Head and Neck Maskless Immobilization Device For Patients With Intracranial Tumors
B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme
Patients Who Receive 131 I-MIBG
Phase I Compare OS in Post-CyberKnife Radiosurgery Tx in 1-3 VS 4 or More Brain Metastases
A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors